Carnegie Capital Asset Management LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, HoldingsChannel reports. The institutional investor purchased 775 shares of the life sciences company’s stock, valued at approximately $236,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Next Capital Management LLC bought a new stake in shares of Illumina during the 2nd quarter valued at about $25,000. Massey Quick Simon & CO. LLC grew its stake in shares of Illumina by 3,100.0% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 96 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 93 shares during the period. North Star Investment Management Corp. bought a new stake in shares of Illumina during the 3rd quarter valued at about $31,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Illumina during the 2nd quarter valued at about $37,000. Finally, Trust Co. of Vermont grew its stake in shares of Illumina by 296.8% during the 3rd quarter. Trust Co. of Vermont now owns 123 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 92 shares during the period. Institutional investors and hedge funds own 91.77% of the company’s stock.
Shares of NASDAQ:ILMN opened at $320.76 on Friday. The stock has a 50 day moving average of $305.50 and a 200 day moving average of $309.86. The company has a market cap of $47.15 billion, a PE ratio of 56.08, a price-to-earnings-growth ratio of 2.36 and a beta of 1.03. The company has a current ratio of 6.82, a quick ratio of 6.15 and a debt-to-equity ratio of 0.41. Illumina, Inc. has a 12-month low of $263.30 and a 12-month high of $380.76.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.53. The company had revenue of $907.00 million during the quarter, compared to the consensus estimate of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.52 EPS. Equities research analysts predict that Illumina, Inc. will post 6.45 earnings per share for the current fiscal year.
In related news, SVP Mostafa Ronaghi sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $300.53, for a total value of $3,005,300.00. Following the transaction, the senior vice president now directly owns 86,585 shares of the company’s stock, valued at approximately $26,021,390.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Phillip G. Febbo sold 155 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $300.00, for a total value of $46,500.00. Following the completion of the transaction, the senior vice president now directly owns 1,506 shares in the company, valued at $451,800. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,193 shares of company stock valued at $4,884,874. 0.38% of the stock is currently owned by corporate insiders.
A number of research firms have issued reports on ILMN. Stifel Nicolaus began coverage on Illumina in a research note on Thursday, November 14th. They set a “buy” rating and a $345.00 price target for the company. ValuEngine downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. BidaskClub upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Guggenheim began coverage on Illumina in a research note on Friday, October 25th. They set a “buy” rating and a $350.00 price target for the company. Finally, Cowen set a $320.00 price target on Illumina and gave the company a “buy” rating in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $333.50.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.